These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 24182769)
1. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. Li L; Liu J; Delohery T; Zhang D; Arendt C; Jones C J Neuroimmunol; 2013 Dec; 265(1-2):82-90. PubMed ID: 24182769 [TBL] [Abstract][Full Text] [Related]
2. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571 [TBL] [Abstract][Full Text] [Related]
3. Teriflunomide and its mechanism of action in multiple sclerosis. Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824 [TBL] [Abstract][Full Text] [Related]
4. Spatial and molecular changes of mouse brain metabolism in response to immunomodulatory treatment with teriflunomide as visualized by MALDI-MSI. Rzagalinski I; Hainz N; Meier C; Tschernig T; Volmer DA Anal Bioanal Chem; 2019 Jan; 411(2):353-365. PubMed ID: 30417265 [TBL] [Abstract][Full Text] [Related]
5. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Medina S; Sainz de la Maza S; Villarrubia N; Álvarez-Lafuente R; Costa-Frossard L; Arroyo R; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM Ann Clin Transl Neurol; 2019 Feb; 6(2):355-363. PubMed ID: 30847367 [TBL] [Abstract][Full Text] [Related]
6. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N Front Immunol; 2021; 12():730342. PubMed ID: 34721394 [TBL] [Abstract][Full Text] [Related]
7. [Teriflunomide (Aubagio). New treatment for multiple sclerosis]. Sabourin G Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397 [TBL] [Abstract][Full Text] [Related]
9. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Fragoso YD; Brooks JB Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857 [TBL] [Abstract][Full Text] [Related]
10. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315 [TBL] [Abstract][Full Text] [Related]
11. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Bar-Or A Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677 [TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for oral therapy in multiple sclerosis. Papadopoulou A; Kappos L; Sprenger T Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro. Jiang L; Zhang W; Li W; Ling C; Jiang M Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW; Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217 [TBL] [Abstract][Full Text] [Related]
15. The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line. Adamczuk G; Humeniuk E; Iwan M; Natorska-Chomicka D; Adamczuk K; Korga-Plewko A Molecules; 2021 Sep; 26(18):. PubMed ID: 34577124 [TBL] [Abstract][Full Text] [Related]
16. Spotlight on teriflunomide. Tallantyre E; Evangelou N; Constantinescu CS Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502 [TBL] [Abstract][Full Text] [Related]
17. Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. Pol S; Sveinsson M; Sudyn M; Babek N; Siebert D; Bertolino N; Modica CM; Preda M; Schweser F; Zivadinov R J Neuroimaging; 2019 Jan; 29(1):52-61. PubMed ID: 30232810 [TBL] [Abstract][Full Text] [Related]
18. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. Iglesias-Bregna D; Hanak S; Ji Z; Petty M; Liu L; Zhang D; McMonagle-Strucko K J Pharmacol Exp Ther; 2013 Oct; 347(1):203-11. PubMed ID: 23892570 [TBL] [Abstract][Full Text] [Related]
19. Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. Malla B; Liotta A; Bros H; Ulshöfer R; Paul F; Hauser AE; Niesner R; Infante-Duarte C Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163469 [TBL] [Abstract][Full Text] [Related]
20. Teriflunomide for the treatment of multiple sclerosis. Warnke C; Stüve O; Kieseier BC Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]